High doses of antipsychotics have been associated with loss in cortical and total gray matter in schizophrenia. However, previous imaging studies have not taken benzodiazepine use into account, in spite of evidence suggesting adverse effects such as cognitive impairment and increased mortality. In this Northern Finland Birth Cohort 1966 study, 69 controls and 38 individuals with schizophrenia underwent brain MRI at the ages of 34 and 43 years. At baseline, the average illness duration was over 10 years. Brain structures were delineated using an automated volumetry system, volBrain, and medication data on cumulative antipsychotic and benzodiazepine doses were collected using medical records and interviews. We used linear regression with intracranial volume and sex as covariates; illness severity was also taken into account. Though both medication doses associated to volumetric changes in subcortical structures, after adjusting for each other and the average PANSS total score, higher scan-interval antipsychotic dose associated only to volume increase in lateral ventricles and higher benzodiazepine dose associated with volume decrease in the caudate nucleus. To our knowledge, there are no previous studies reporting associations between benzodiazepine dose and brain structural changes. Further studies should focus on how these observations correspond to cognition and functioning.
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Introduction
Progressive changes in the brain structures of individuals with schizophrenia compared to healthy controls have been reported especially in frontal and temporal lobes, anterior cingulate, hippocampus, amygdala, thalamus and insula (Shepherd et al., 2012; Torres et al., 2013) . The possible effects of antipsychotics on brain structure and functioning have been of intensive study in recent years (Andreasen et al., 2013; Ho et al., 2011; Radua et al., 2012) , and a meta-review concluded that previous comparisons between healthy controls and people with schizophrenia may be, at least partly, confounded by the effects of medication (Shepherd et al., 2012) . However, in spite of several reviews and meta-analyses (Fusar-Poli et al., 2013; RoizSantiáñez et al., 2015; Vita et al., 2015) on the association between antipsychotics and brain volume changes, the results are inconclusive with a need for further studies.
Many imaging studies in schizophrenia are conducted in the early phase of the illness, mostly during the first episode, when the possible 
